Literature DB >> 20216162

Pulmonary hypertension in children: a historical overview.

Steven H Abman1.   

Abstract

Pulmonary arterial hypertension in children contributes significantly to morbidity and mortality in diverse pediatric cardiac, lung, hematologic, and other diseases. Pulmonary arterial hypertension is generally a disease of small pulmonary arteries characterized by vascular narrowing due to high-tone and abnormal vasoreactivity, structural remodeling of the vessel wall, intraluminal obstruction, and decreased vascular growth and surface area. Without therapy, high pulmonary vascular resistance contributes to progressive right ventricular failure, low cardiac output, and death. Advances in basic pulmonary vascular biology over the last few decades have led directly to several novel therapies, which have significantly expanded therapeutic choices and have led to improved survival and quality of life of many children with pulmonary arterial hypertension. Despite these improvements, long-term outcomes in many settings remain guarded and substantial challenges persist, especially with regard to understanding mechanisms and approach to structural remodeling of severe pulmonary arterial hypertension.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20216162     DOI: 10.1097/PCC.0b013e3181c765f3

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  8 in total

1.  Phosphodiesterase 4 inhibition attenuates persistent heart and lung injury by neonatal hyperoxia in rats.

Authors:  Yvonne P de Visser; Frans J Walther; El Houari Laghmani; Paul Steendijk; Maaike Middeldorp; Arnoud van der Laarse; Gerry T M Wagenaar
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-09-23       Impact factor: 5.464

2.  Food and Drug Administration (FDA) postmarket reported side effects and adverse events associated with pulmonary hypertension therapy in pediatric patients.

Authors:  Dawn M Maxey; D Dunbar Ivy; Michelle T Ogawa; Jeffrey A Feinstein
Journal:  Pediatr Cardiol       Date:  2013-03-27       Impact factor: 1.655

3.  The pharmacology of acute lung injury in sepsis.

Authors:  Brian Michael Varisco
Journal:  Adv Pharmacol Sci       Date:  2011-06-28

4.  Oxidative injury of the pulmonary circulation in the perinatal period: Short- and long-term consequences for the human cardiopulmonary system.

Authors:  Daphne P de Wijs-Meijler; Dirk J Duncker; Dick Tibboel; Ralph T Schermuly; Norbert Weissmann; Daphne Merkus; Irwin K M Reiss
Journal:  Pulm Circ       Date:  2017-01-01       Impact factor: 3.017

5.  Pulmonary arterial hypertension in the USA: an epidemiological study in a large insured pediatric population.

Authors:  Lin Li; Susan Jick; Stefanie Breitenstein; Gemzel Hernandez; Alexander Michel; David Vizcaya
Journal:  Pulm Circ       Date:  2017-02-01       Impact factor: 3.017

6.  Increased risk of pulmonary hypertension following premature birth.

Authors:  Estelle Naumburg; Lars Söderström
Journal:  BMC Pediatr       Date:  2019-08-17       Impact factor: 2.125

Review 7.  Biomarkers for pediatric pulmonary arterial hypertension - a call to collaborate.

Authors:  Kelley L Colvin; Melanie J Dufva; Ryan P Delaney; D Dunbar Ivy; Kurt R Stenmark; Michael E Yeager
Journal:  Front Pediatr       Date:  2014-02-03       Impact factor: 3.418

Review 8.  Macrophage migration inhibitory factor (MIF) in the development and progression of pulmonary arterial hypertension.

Authors:  Mohamed Ahmed; Edmund Miller
Journal:  Glob Cardiol Sci Pract       Date:  2018-06-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.